Comparative Pharmacology
Head-to-head clinical analysis: SECOBARBITAL SODIUM versus SODIUM BUTABARBITAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SECOBARBITAL SODIUM versus SODIUM BUTABARBITAL.
SECOBARBITAL SODIUM vs SODIUM BUTABARBITAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Secobarbital enhances the activity of gamma-aminobutyric acid (GABA) at GABA-A receptors, increasing chloride ion influx and causing neuronal hyperpolarization, leading to CNS depression.
Barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing CNS depression.
Oral: 100-200 mg at bedtime for insomnia; IM: 150-200 mg as a single dose; IV: 50-250 mg as a single dose, administered slowly (not to exceed 50 mg per 15 seconds).
50-100 mg orally or intramuscularly 3-4 times daily as a sedative; 100-200 mg orally or intramuscularly for preoperative sedation.
None Documented
None Documented
Terminal elimination half-life is approximately 15-40 hours (mean ~30 hours) in adults. In neonates, half-life may be prolonged (up to 100 hours). Half-life increases in hepatic impairment and with advanced age.
Terminal elimination half-life 40-60 hours in adults; prolonged in hepatic impairment and elderly.
Renal excretion of unchanged drug (about 25-50%) and metabolites; the remainder is eliminated via hepatic metabolism and fecal excretion. Less than 5% is excreted unchanged in feces.
Renal excretion of unchanged drug and metabolites; approximately 30-50% as unchanged drug in urine. Minor fecal elimination (<5%).
Category D/X
Category C
Barbiturate
Barbiturate